Purpose: The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (Iressa ) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who are refractory to a previous chem otherapy regim en.
Purpose: The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (Iressa ) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who are refractory to a previous chem otherapy regim en.
Materials and Methods: Twenty-five patients who were refractory to previous chem otherapy were selected for this study. 
